lonapegsomatropin Updated Sep 1
Skytrofa is a steady commercial contributor but not the primary value driver for ASND anymore, YORVIPATH's rapid growth and the YUVIWEL launch are the main catalysts. Watch for any FDA filing for adult GHD indication (completed Phase 3 data in hand) and quarterly Skytrofa sales trajectory. The stock's next major binary catalyst is the EU MAA decision for YUVIWEL expected in Q4 2026.
- Once-weekly dosing is a clear convenience advantage over daily somatropin injections, supporting market share gains in pediatric GHD.
- Skytrofa generated €55M in Q2 2026 revenue as part of ASND's total €315M product revenue (+105% YoY), showing commercial traction.
- Completed Phase 3 adult GHD trials provide a potential label expansion opportunity that could double the addressable market.
- Skytrofa faces competition from established daily somatropin products (Genotropin, Norditropin) and other long-acting GH products, limiting pricing power.
- Multiple large institutional holders (FMR, Capital World, Morgan Stanley, Goldman Sachs) fully exited ASND positions in Q2 2026, signaling potential concern about valuation or competitive positioning.
- Skytrofa is now the #2 product for ASND behind YORVIPATH (€252M vs €55M in Q2), meaning the stock's thesis is less dependent on this drug.